Ask Warren

Dongwha Pharm

000020 · KOSPI · ₩000020 · 동화약품

₩5,100▼ ₩60 (1.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩137B₩131B₩124B₩122B₩125B₩126B₩121B₩110B
Cost of sales₩78B₩71B₩72B₩67B₩69B₩71B₩66B₩60B
Gross profit₩59B₩60B₩52B₩55B₩56B₩55B₩55B₩51B
Operating income₩10B₩11B−₩4B₩1.4B₩614M₩2.3B₩2.8B−₩582M
Net income−₩3.2B₩9.7B₩3.6B−₩5.9B₩6.9B−₩800M₩4.2B−₩5.2B
Net income to shareholders₩6.6B₩10B₩454M₩957M₩7.2B₩34M−₩640M−₩308M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩654B₩648B₩642B₩655B₩643B₩625B₩620B₩587B
Current assets₩237B₩226B₩218B₩236B₩232B₩240B₩238B₩218B
Cash and equivalents₩22B₩11B₩13B₩12B₩17B₩19B₩26B₩22B
Total liabilities₩238B₩238B₩241B₩253B₩241B₩228B₩218B₩182B
Current liabilities₩194B₩195B₩203B₩153B₩143B₩138B₩134B₩109B
Borrowings₩107B₩105B₩102B₩102B₩85B₩79B₩76B₩58B
Total equity₩415B₩410B₩401B₩402B₩402B₩397B₩402B₩405B
Shareholders' equity₩395B₩388B₩380B₩378B₩377B₩370B₩373B₩376B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩18B₩697M₩9.7B−₩1.4B₩4.6B₩2.8B−₩1.5B−₩8.3B
Capital spending₩2.5B₩3.6B₩6.5B₩17B₩16B₩13B₩11B₩11B
Free cash flow₩16B−₩2.9B₩3.2B−₩19B−₩12B−₩10B−₩12B−₩20B
Dividends paid₩0₩1.8B₩10B₩0−₩5B₩0₩0₩0

Consolidated where available. Amounts in won.

Also known as: Dongwha Pharm / 동화약품 / 000020 / KRX:000020

Source: KRX statistical information